A woman who said asbestos in Johnson & Johnson talcum-based products caused her cancer was awarded $29 million by a California jury. The drugmaker is planning to appeal and denies that talc in its products causes cancer. J&J is facing more than 13,000 similar lawsuits. (Reuters)

An increase in mental health disorders has been linked to social media’s rise, according to research published by the American Psychological Association. The study found that those born in 1995 or later suffered from negative psychological symptoms, with the spike occurring in 2011. The same trends were not found in those 26 years and older. (NBC)

The U.S. patent office has rejected Alvogen’s petition to challenge Celgene’s myeloma drug Revlimid. The blockbuster cancer drug earned $2.55 billion in revenue in Q4 of 2018. (Reuters) In 2022, it may lose exclusivity in the U.S. This decision comes as Bristol-Myers Squibb defends its decision to acquire Celgene amid backlash from shareholders. (Endpoints)

What do we know about Amazon, J.P. Morgan, and Berkshire Hathaway’s healthcare venture? The nonprofit was announced in January 2018 with the goal of improving healthcare for the three companies’ 1.2 million employees. More than a year later, it was branded “Haven.” Here’s a breakdown of what else is known about and expected from Haven. (CNBC)

This week’s roundup of people moves includes Greater Than One’s hiring of Ross Thomson as chief creative officer and promotions at PatientPoint and Dudnyk. Read on to learn about other notable hirings and promotions in pharma and healthcare marketing. (MM&M)